Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

15,733

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

15,733 results for “article”

Learn how ShareScore rates datasets ↗
zenodo16/100

Dataset related to article "Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis"

<p>This record contains raw data related to article &quot;Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis&quot;</p> <p>The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT.</p> <p>MATERIALS AND METHODS:</p> <p>The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status.</p> <p>RESULTS:</p> <p>A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed.</p> <p>CONCLUSIONS:</p> <p>A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.</p> <p>&nbsp;</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis"

<p>This record contains raw data related to article &quot;Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis&quot;</p> <p>OBJECTIVE::</p> <p>To evaluate hypofractionated radiation therapy (HFRT) given at therapeutic effective doses in a phase II study. Endpoints were progression-free survival (PFS) rate, overall survival (OS), and incidence of toxicity.</p> <p>METHODS::</p> <p>Patients with newly diagnosed glioblastoma, age ⩾70 years, Karnofsky performance scale (KPS) score ⩽60, were enrolled. The total dose of HFRT was 52.5 Gy/15 fractions, corresponded to a biological effective dose to the tumor of 70.88 Gy.</p> <p>RESULTS::</p> <p>Thirty patients were treated, with a median age of 75 years. Concurrent and adjuvant temozolomide chemotherapy (TMZ-CHT) was administered in 7 (23.3%) and 11 (40.7%) patients received only adjuvant TMZ-CHT. The median, 6-month PFS, and 12-month PFS were 5.0 months, 43.3%, and 20%, respectively. The median, 6-month OS, and 12-month OS were 8 months, 90%, and 30%, respectively. At the last observation time, 26 patients (86.7%) were dead and 4 (13.3%) were alive. No increase in steroid drugs was required during radiotherapy treatment and a reduction was possible in 12 (40%). Patients with KPS=60, RPA V, MGMT methylated status, neurological status stable or improved after surgery and who underwent HFRT with concurrent and adjuvant CHT, had the better outcome.</p> <p>CONCLUSION::</p> <p>HFRT has proven to be feasible and effective, with limited morbidity, for selected elderly and frail patients with newly diagnosed glioblastoma. The primary objective of this study was not reached in the whole cohort but only in selected patients, who need more aggressive treatment.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling"

<p>this record contains raw data related to article &quot;A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling&quot;</p> <p>BACKGROUND:</p> <p>Invasive fungal infections (IFI) represent a common side effect of allogeneic hematopoietic stem cell transplant (allo-SCT), resulting in increased non relapse mortality (NRM) and reduced overall survival (OS) rates. Seventy-five days of Fluconazole 400&nbsp;mg/d represents the standard primary antifungal prophylaxis (PAP) after allo-SCT, especially for low-risk transplants. However, the ideal dosage of fluconazole has never been tested.</p> <p>METHODS:</p> <p>Here, we report the experience of our institution on 113 consecutive patients receiving an allo-SCT from a HLA identical sibling between 1999 and 2015, where PAP consisted of fluconazole 100&nbsp;mg/d only during the pre-engraftment phase. At the time of transplant, all patients were considered at low-risk for mold infection according to ECIL-5 guidelines.</p> <p>RESULTS:</p> <p>Cumulative incidence of possible-probable-proven IFI was 11.7%, while proven-probable (PP-IFI) occurred in 5.5% of patients by day 100 post transplant. Of note, only 1 patient developed invasive Candidiasis due to a non-albicans strain and stool-screening tests were negative for colonization by Candida albicans species. The incidence of 1-year acute and 2-year chronic graft-versus-host-disease (GVHD) was 30% and 45%, respectively. Three-year OS and 1-year NRM were 53% and 11.3%, respectively.</p> <p>CONCLUSION:</p> <p>In summary, fungal prophylaxis with fluconazole 100&nbsp;mg/d results in very low incidence of PP-IFI, GVHD and NRM in low-risk allo-SCT.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer comparison of costs and outcomes at a single institute"

<p>This record contains raw data related to article &quot;Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer comparison of costs and outcomes at a single institute&quot;</p> <p>Background:</p> <p>Robotic surgery is increasingly used to resect lung cancer. However costs are high. We compared costs and outcomes for robotic surgery, video-assisted thoracic surgery (VATS), and open surgery, to treat non-small cell lung cancer (NSCLC).</p> <p>Methods:</p> <p>We retrospectively assessed 103 consecutive patients given lobectomy or segmentectomy for clinical stage I or II NSCLC. Three surgeons could choose VATS or open, the fourth could choose between all three techniques. Between-group differences were assessed by Fisher&#39;s exact, two-way analysis of variance (ANOVA), and Wilcoxon-Mann-Whitney test. P values &lt;0.05 were considered significant.</p> <p>Results:</p> <p>Twenty-three patients were treated by robot, 41 by VATS, and 39 by open surgery. Age, physical status, pulmonary function, comorbidities, stage, and perioperative complications did not differ between the groups. Pathological tumor size was greater in the open than VATS and robotic groups (P=0.025). Duration of surgery was 150, 191 and 116 minutes, by robotic, VATS and open approaches, respectively (P&lt;0.001). Significantly more lymph node stations were removed (P&lt;0.001), and median length of stay was shorter (4, 5 and 6 days, respectively; P&lt;0.001) in the robotic than VATS and open groups. Estimated costs were 82%, 68% and 69%, respectively, of the regional health service reimbursement for robotic, VATS and open approaches.</p> <p>Discussion:</p> <p>Robotic surgery for early lung cancer was associated with shorter stay and more extensive lymph node dissection than VATS and open surgery. Duration of surgery was shorter for robotic than VATS. Although the cost of robotic thoracic surgery is high, the hospital makes a profit.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer"

<p>This record contains raw data related to article &quot;The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer&quot;</p> <p>BACKGROUND:</p> <p>Diagnoses of oligometastatic prostate cancer (PC) increased in the recent years thanks to the advancement in imaging and more effective systemic therapies. Here we evaluate the efficacy of Stereotactic Body Radiation Therapy (SBRT) in oligorecurrent and oligoprogressive PC.</p> <p>METHODS:</p> <p>We included patients with a maximum of five metastases diagnosed in a maximum of two target organs. Concomitant treatment with hormonal therapies or chemotherapies was allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), out-field progression free survival, overall progression free survival (PFS), and overall survival.</p> <p>RESULTS:</p> <p>We included in the analysis 64 patients treated on 90 metastases. Fifty (78.1%) patients were treated on lymph nodes, 2 (3.1%) patients simultaneously on lymph node and bone while 10 (15.7%) patients on bone only. Lung metastases were treated in 2 (3.1%) patients. Thirty-seven (57.81%) were without androgen deprivation therapy when treated with SBRT. Median follow-up was 15.2&nbsp;months. Rates of LC at 6-, 12-, and 18- months were 94%, 88%, and 84%, respectively. Oligoprogressive patients compared to oligorecurrent (HR 9.10, P&nbsp;=&nbsp;0.049) and prolongation of time from diagnosis of metastases to SBRT (HR 1.03, P&nbsp;=&nbsp;0.047) were associated with worse LC. Median PFS was 6.6&nbsp;months (range 1.1-42.4). Castration resistant patients experienced worse PFS compared to castration sensitive group (HR 2.12, P&nbsp;=&nbsp;0.021).</p> <p>CONCLUSIONS:</p> <p>Stereotactic body radiation therapy seems to be an effective treatment for metastases from PC. Prospective trials are necessary to better define selection of patients and to evaluate combination of SBRT and new systemic drugs in castration resistant patients.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"

<p>This record contains raw data related to article &quot;Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up&quot;</p> <p>BACKGROUND:</p> <p>The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial.</p> <p>METHODS AND MATERIALS:</p> <p>5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions.</p> <p>RESULTS:</p> <p>A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1&thinsp;years. One, three and 5 year LC rates were 94&thinsp;&plusmn;&thinsp;3.1%, 78.0&thinsp;&plusmn;&thinsp;5.9% and 78.0&thinsp;&plusmn;&thinsp;5.9%, without reaching the median LC time. Median OS was 27.6&thinsp;months and the survival rates were 85.2&thinsp;&plusmn;&thinsp;4.5%, 31.1&thinsp;&plusmn;&thinsp;5.9% and 18.0&thinsp;&plusmn;&thinsp;4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p&nbsp;=&thinsp;0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1&thinsp;year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected.</p> <p>CONCLUSIONS:</p> <p>Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy"

<p>This record contains raw data related to article<br> &quot;Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy&quot;</p> <p>Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival.</p> <p>MATERIALS AND METHODS:</p> <p>We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS).</p> <p>RESULTS:</p> <p>437 metastases were treated in 270 patients. Lung was site of metastases in 48.5% of cases, followed by liver (36.4%). Systemic treatment was administered before SBRT in 199 patients (73.7%). Median follow-up time was 23 months (3-98.7). Rates of LC at 1, 3 and 5 years were 95%, 73% and 73%, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5%, 56.6%, and 37.2%, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS.</p> <p>CONCLUSIONS:</p> <p>Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article: SENSE OF OWNERSHIP INFLUENCE ON TACTILE PERCEPTION: IS THE PREDICTIVE CODING ACCOUNT VALID FOR THE SOMATIC RUBBER HAND ILLUSION?

<p><strong><span>Table including demographic data (sex, age, and education), Laterality Quotient score, Proprioceptive drift data, Body Ownership Questionnaire data, and Two-Point Discrimination score</span></strong></p>

restrictedAug 2024View details →
zenodo16/100

Data and code used in the article "Integrating multiphysics processes with deep learning for the Prediction of coupled water-vapor-heat water fluxes in unsaturated zone"

<p>《Integrating multiphysics processes with deep learning for the Prediction of coupled water-vapor-heat water fluxes in unsaturated zone》 (the paper has been submitted to&nbsp;<em>Water Resources Research</em>). The data and code used in the paper, specifically, the water content data and temperature data from in-situ observations from July 1, 2020 to August 29, 2020 (with a frequency of observations of 5 min), and the sample code for implementing cpinn using python (mainly the tensorflow library). These data can help readers better understand and replicate our study. All data and code have been uploaded.</p> <p>The paper has been submitted to <em>Water Resources Research</em>, if the paper is accepted for publication, all data will be made&nbsp;freely available.</p> <p>.</p> <p>&nbsp;</p>

restrictedcc-by-4.0Aug 2024View details →
zenodo16/100

Data set for the article 'Electroreduction of CO to 2.8 A cm-2 C2+ Products: Maximizing Efficiency with Minimalist Electrode Design Featuring a Mesopore-Rich Hydrophobic Copper Catalyst Layer'

<p>This depository contains the data set for the article 'Electroreduction of CO to 2.8 A cm-2 C2+ Products: Maximizing Efficiency with Minimalist Electrode Design Featuring a Mesopore-Rich Hydrophobic Copper Catalyst Layer' (<a href="https://doi.org/10.1002/advs.202405938">https://doi.org/10.1002/advs.202405938</a>)</p>

restrictedcc-by-4.0Aug 2024View details →
zenodo16/100

Bibliometric Analysis of Exhibition and Trade Fair Research: A Corpus of 69 Articles and Cluster Insights from Journal of Convention and Event Tourism

<p>This dataset comprises a bibliometric analysis of 69 articles focused on the exhibition and trade fair sector, drawn from Scopus-indexed publications within the <em>Journal of Convention and Event Tourism</em>. The dataset includes detailed information on authorship, publication trends, and the clustering of research themes, providing valuable insights into the academic landscape of this niche within the MICE (Meetings, Incentives, Conferences, and Exhibitions) industry. This resource is essential for researchers and professionals seeking to understand the development and focus areas of scholarly work in exhibitions and trade fairs</p>

restrictedcc-by-4.0Aug 2024View details →
zenodo16/100

Dataset from the article "A comparative analysis between two flax varieties indicates lignan-mediated salt stress adaptiveness"

<p>This is a collection of raw data of the independent variables from the original research article &ldquo;A comparative analysis between two flax varieties indicates lignan-mediated salt stress adaptiveness&rdquo;.</p> <p>&nbsp;</p> <p>The file contents and descriptions are as follows:</p> <ol> <li>Biochemical Data.xlsx. This file contains the data of SOD, CAT, APX, GPOX, ROS, MDA, Proline, DPPH antioxidants, polyphenols, and phenolic acid assays.</li> <li>Genomic Data.xlsx. This file contains the Cq values of Cyklophilin, ETIF5A, microRNA 168a, microRNA 399g, and microRNA 828a obtained using the two-tailed qPCR assay.</li> <li>Morphological Data.xlsx. This file contains data on shoot-root length, root diameter, root volume, root branching, shoot-root weight, leaf count, and leaf relative water content assays.</li> </ol> <p>&nbsp;</p>

restrictedcc-by-4.0Oct 2024View details →
zenodo16/100

Dataset related to the article "The potential of sound analysis to reveal hemodynamic conditions of arteriovenous fistulae for hemodialysis"

<p>The dataset contains a folder for each patient including for each follow-up:</p> <p>- MR images used to generate the 3D AVF model for the computational fluid dynamic simulations</p> <p>- US images used to derive the AVF patient-specific boundary conditions for the computational fluid dynamic simulations</p> <p>- AVF sound recordings</p> <p>- Two files containing the post-processing of simulation results (cross-sectional areas of the AVF vessels and the surface map of the Oscillatory Shear Index)</p>

restrictedcc-by-4.0Oct 2024View details →
zenodo16/100

Dataset related to the article "Head to Head Comparison between Different 3-Dimensional Echocardiographic Rendering Tools in the Imaging of Percutaneous Edge-to-Edge Mitral Valve Repair"

<p>This record contains raw data related to the article &quot;Head to Head Comparison between Different 3-Dimensional Echocardiographic Rendering Tools in the Imaging of Percutaneous Edge-to-Edge Mitral Valve Repair&quot;</p> <p>MitraClip (MC) is the most common percutaneous treatment for severe mitral regurgitation<br> (MR). An accurate two-dimensional and three-dimensional echocardiographic (3DTEE) imaging is<br> mandatory for the optimal procedural result. Recently transillumination 3DTEE rendering (3DTr) has<br> been introduced integrating a virtual light source into the dataset and with the addition of glass effect<br> (3DGl) allows to adjust tissue transparency improving depth perception and anatomical structure<br> delineation in comparison with the standard 3DTEE (3DSt). The aim of this retrospective study in<br> 30 patients undergoing MC, was to compare 3DSt, 3DTr, and 3DGl in mitral valve (MV) evaluation<br> and procedural result assessment. 3DTEE acquisitions obtained before and after MC were processed<br> with 3DSt, 3DTr, and 3DGl rendering. Each reconstruction was scored for quality and for ability<br> to recognize MV anatomy, MR origin, clip position, dimension and grasping. Imaging quality was<br> judged good or optimal in 52%, 76%, and 96% in 3DSt, 3DTr, and 3DGl reconstructions respectively.<br> In 26/30 patients a diagnostic incremental value was found with 3DTr vs. 3DSt and in 15/26 with<br> 3DGl vs. 3DTr and 3DSt. Only 3DGl with perpendicular cropping of the clip allowed to visualize and<br> measure the grasped portion of each mitral leaflets. 3DTEE imaging during MC may be improved<br> by 3DTr and 3DGl providing a better evaluation of MV, of leaflet grasping and of residual MR jets<br> after MC.</p>

restrictedJun 2021View details →
zenodo16/100

Dataset related to article "Volume-of-Interest Aware Deep Neural Networks for Rapid Chest CT-Based COVID-19 Patient Risk Assessment"

<p>This record contains raw data related to article &ldquo;Volume-of-Interest Aware Deep Neural Networks for Rapid Chest CT-Based COVID-19 Patient Risk Assessment&quot;</p> <p>Since December 2019, the world has been devastated by the Coronavirus Disease 2019 (COVID-19) pandemic. Emergency Departments have been experiencing situations of urgency where clinical experts, without long experience and mature means in the fight against COVID-19, have to rapidly decide the most proper patient treatment. In this context, we introduce an artificially intelligent tool for effective and efficient Computed Tomography (CT)-based risk assessment to improve treatment and patient care. In this paper, we introduce a data-driven approach built on top of volume-of-interest aware deep neural networks for automatic COVID-19 patient risk assessment (discharged, hospitalized, intensive care unit) based on lung infection quantization through segmentation and, subsequently, CT classification. We tackle the high and varying dimensionality of the CT input by detecting and analyzing only a sub-volume of the CT, the Volume-of-Interest (VoI). Differently from recent strategies that consider infected CT slices without requiring any spatial coherency between them, or use the whole lung volume by applying abrupt and lossy volume down-sampling, we assess only the &quot;most infected volume&quot; composed of slices at its original spatial resolution. To achieve the above, we create, present and publish a new labeled and annotated CT dataset with 626 CT samples from COVID-19 patients. The comparison against such strategies proves the effectiveness of our VoI-based approach. We achieve remarkable performance on patient risk assessment evaluated on balanced data by reaching 88.88%, 89.77%, 94.73% and 88.88% accuracy, sensitivity, specificity and F1-score, respectively.</p>

restrictedMay 2021View details →
zenodo16/100

Dateset related to article "Spinocerebellar Ataxia Type 1: One‑Year Longitudinal Study to Identify Clinical and MRI Measures of Disease Progression in Patients and Presymptomatic Carriers "

<p>This dataset contains clinical information (neuropsychological evaluations, structural MRI measures, etc.) on patients with Spinocerebellar Ataxia included in the study reported at title</p>

restrictedAug 2021View details →
zenodo16/100

Figure 3. Caprella penantis Leach, 1814 in REVIEW ARTICLE Caprellids (Crustacea: Amphipoda) from the Gulf of Mexico, with observations on Deutella mayeri, redescription of Metaprotella hummelincki, a taxonomic key and zoogeographical comments

Figure 3. Caprella penantis Leach, 1814. Texas, USA; BRTC 2–9108. Scale bar: 1 mm.

opennotspecifiedJul 2014View details →
zenodo16/100

Dataset related to article "BEING ADULTS WITH CEREBRAL PALSY: RESULTS OF A MULTICENTER ITALIAN STUDY ON QUALITY OF LIFE AND PARTICIPATION"

<p>For each participant, we collected the following:<br> &ndash; Principal clinical details.<br> &ndash; Level of severity (I best&ndash;V worst) according to the Gross Motor Function Classification System (GMFCS) Manual Ability Classification System (MACS) , the Communication Function Classification System (CFCS).<br> &ndash; Neuroradiological documentation classified in accordance with the Surveillance of Cerebral Palsy in Europe working group&nbsp;<br> After receiving written informed consent, participants completed the following protocol:<br> &ndash; Specific questionnaires to assess: (a) Quality of life: the SF-36&nbsp; (b) Participation: LIFE-H (c) Socio-economic status (SES, Hollingshead index&nbsp;<br> &ndash; A semi-structured interview based on parameters agreed between the various centers and designed to obtain information concerning(a) General state of health and aspects of daily life relating to<br> their occupation, free time, and autonomy; (b) Affective relations and capacity for self-observation of<br> their inner world, investigating emotions, affections, and feelings, such as anger, sadness, and happiness</p> <p>&nbsp;</p>

restrictedAug 2021View details →
zenodo16/100

dataset related to article "TEMPORAL LOBE EPILEPSY SURGERY IN CHILDREN AND ADULTS: A MULTICENTER STUDY"

<p>XLSX: General characteristics, neuroimaging, and electroclinical features of BESTA patients included in the study</p>

restrictedAug 2021View details →
zenodo16/100

Dataset related to article "FOCAL CORTICAL DYSPLASIA IIIA IN HIPPOCAMPAL SCLEROSIS-ASSOCIATED EPILEPSY: ANATOMO-ELECTRO-CLINICAL PROFILE AND SURGICAL RESULTS FROM A MULTICENTRIC RETROSPECTIVE STUDY"

<p>XLSX clinical database: General characteristics, neuroimaging, and electroclinical features of BESTA patients included in the study</p>

restrictedAug 2021View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.